Piper Sandler Gives a Buy Rating to NeoGenomics (NEO)
NeoGenomics Analyst Ratings
BTIG Maintains Buy on NeoGenomics, Lowers Price Target to $21
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO) and Envista Holdings (NVST)
Buy Rating Affirmed for NeoGenomics Amid Strong Q1 Performance and Growth Prospects
TD Cowen Maintains Buy on NeoGenomics, Lowers Price Target to $20
Craig-Hallum Assumes NeoGenomics at Buy, Announces Price Target of $26
NeoGenomics Analyst Ratings
Benchmark: Reiterates NeoGenomics (NEO.US) rating, adjusted from buy to buy rating, target price $18.00.
Benchmark Reiterates Buy on NeoGenomics, Maintains $18 Price Target
Needham: Maintaining the NeoGenomics (NEO.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $24.00 to $19.00.
NeoGenomics Analyst Ratings
NeoGenomics Surpasses Q1 Expectations With Strong NGS Growth and Enhanced Profitability: Maintaining a Buy Rating
Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating
Leerink Partners Keeps Their Buy Rating on NeoGenomics (NEO)
What 6 Analyst Ratings Have To Say About NeoGenomics
Neo Performance Materials Analyst Ratings
NeoGenomics Analyst Ratings
NeoGenomics Analyst Ratings
Buy Rating Affirmed for NeoGenomics Amidst Strong Growth and Strategic Market Positioning
No Data